Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model for AI-powered decision-making in Life Sciences

Komodo also unveils new Marmot capabilities to move organizations beyond AI experimentation and into enterprise-wide intelligence

Komodo Health®, the leader in AI-powered healthcare intelligence, today announced an expanded strategic partnership with Alnylam Pharmaceuticals (NASDAQ:ALNY), the leading RNAi therapeutics company to scale Marmot™, Komodo’s analytics AI platform, across key enterprise functions at Alnylam.

Built on the Healthcare Map®, the industry’s most comprehensive view of more than 330 million de-identified patient journeys, Marmot helps organizations move beyond fragmented analytics and static reporting toward real-time, transparent, and reproducible healthcare intelligence. Launched in August 2025, Alnylam was an early adopter of the platform, with the collaboration initially focused on building custom AI agents for Alnylam’s commercial business function.

The expanded partnership will enable Alnylam to deploy Marmot across its customer-facing organization and leverage its capabilities more broadly across the enterprise, creating a unified foundation for data-driven decision-making at scale.